Effect of 4 Weeks Treatment With Acipimox in Patients With Chronic Heart Failure (ACME)

University of Aarhus

Status: Completed

Conditions: Heart Failure

Treatments: Drug: acipimox; Drug: placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT00549614

20061218

Details and patient eligibility

About

The primary objective of this study is to evaluate whether metabolic modulation improves left ventricular function, work capacity, insulin sensitivity and modifies substrate metabolism in chronic heart failure

Enrollment: 28 estimated patients

Sex: All

Ages: 30 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• EF<40 %
• IHD
• NYHA-class II-III.

Exclusion criteria

• pregnancy
• severe renal failure
• new brady- or tachyArrhythmia
• Severe stenotic valvular disease
• myocardial infarction within last 6 weeks
• insulin treated diabetes mellitus
• peptic ulcer
• pregnancy or lactating women
• allergy towards tested medicine

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

28 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: acipimox

2

Placebo Comparator group

Treatment:

Drug: placebo